治療不十分な本態性高血圧の日本人患者におけるエサキセレノンとトリクロルメチアジドの有効性および安全性に対する肥満度指数(BMI)の影響:EXCITE-HT試験のサブ解析
Effect of Body Mass Index on the Efficacy and Safety of Esaxerenone Versus Trichlormethiazide for the Treatment of Japanese Patients with Uncontrolled Essential Hypertension: A Subanalysis of the Excite-HT Study.
Katsuya Tomohiro, Kario Kazuomi, Ohishi Mitsuru, Shimosawa Tatsuo ほか — Journal of clinical hypertension (Greenwich, Conn.)
AI要約
治療不十分な高血圧の日本人患者を対象に、エサキセレノンとトリクロルメチアジドの有効性・安全性をBMI別に比較。エサキセレノンはBMIに関わらず血圧を効果的に下げ、忍容性も良好。早朝の血圧低下ではトリクロルメチアジドより優れる可能性が示唆された。
AI生成の要約です — 原文を読む
Abstract(原文)
This prespecified, exploratory, body mass index (BMI)-stratified analysis of the randomized, open-label EXCITE-HT study examined whether esaxerenone elicits a blood pressure (BP)-lowering effect similar to trichlormethiazide in Japanese patients with uncontrolled essential hypertension. Patients received either esaxerenone or trichlormethiazide for 12 weeks and were grouped by baseline BMI: <25 kg/m (low) or ≥25 kg/m (high). The primary endpoint was change in morning home systolic/diastolic BP (SBP/DBP). Among 585 patients, 157 and 135 with low BMI received esaxerenone and trichlormethiazide, respectively; in the high BMI subgroup, 138 and 155 patients received esaxerenone or trichlormethiazide. The least squares mean between-group differences (esaxerenone-trichlormethiazide) were -2.1 mmHg (95% confidence interval [-4.1, -0.1])/-0.1 mmHg (-1.2, 1.0) and -2.0 mmHg (-4.0, -0.1)/-1.0 mmHg (-2.2, 0.2) for SBP/DBP in the low and high BMI subgroups, respectively. Bedtime home and office BP showed comparable tendencies. The incidence of serum potassium <3.5 mEq/L was more common with trichlormethiazide, whereas serum potassium ≥5.5 mEq/L occurred more frequently with esaxerenone; serum potassium never reached ≥6.0 mEq/L in any subgroup. Both drugs showed transient, modest decreases in creatinine-based estimated glomerular filtration rate that stabilized by Week 12. These exploratory findings, consistent with the primary study results, suggest that esaxerenone provides effective and well-tolerated BP control regardless of baseline BMI and may lower early-morning SBP to a greater extent than trichlormethiazide.
このコラムに関連する書籍
高血圧を食事で改善する――DASH食と減塩の実践ガイド
循環器・栄養学関連書籍
カリウムを増やしナトリウムを減らすDASH食の実践法を、日本の食材・料理に合わせて解説。
Amazonで本を見るおいしい減塩レシピ――1日6g以下を無理なく続ける
管理栄養士監修
塩分を抑えながら満足度の高い食事を実現するコツとレシピを紹介。カリウム食材の活用法も掲載。
Amazonで本を見るAmazonのアソシエイトとして、栄養DBは適格販売により収入を得ています。
出典: PubMed (PMID: 42316368)。AI要約は情報提供のみを目的とし、医療的アドバイスを構成するものではありません。